<unk>  linking a T cell to a malignant B cell.<unk>  is a bispecific T-cell engager (BiTE). It enables a patient's T cells to recognize malignant B cells. A molecule of<unk>  combines two binding sites: a CD3 site for T cells and a CD19 site for the target B cells. CD3 is part of the T cell receptor. The drug works by linking these two cell types and activating the T cell to exert cytotoxic activity on the target cell. CD3 and CD19 are expressed in both pediatric and adult patients, making<unk>  a potential therapeutic option for both pediatric and adult populations.
Blinatumomab
Loncastuximab tesirine
Margetuximab
Tositumomab
Siltuximab
Dinutuximab
Isatuximab
Polatuzumab vedotin